CXCR4 and neoplasm: For example, disrupting CXCL12-CXCR4 signaling by AMD3100, a small molecule inhibitor of CXCR4, demonstrated a synergistic anti-tumor activity in combination with anti-PD-1/PD-L1 therapy in mouse models of PDAC (84, 89).